APA (7th ed.) Citation

M, J., D, H., I, B., P, S., V, G., F, R., . . . LL, S. (2025). First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma. Investigational new drugs, 43(2), 284. https://doi.org/10.1007/s10637-025-01518-7

Chicago Style (17th ed.) Citation

M, Johnson, et al. "First-in-human, Phase 1 Dose Escalation Study of SL-279252, a Hexameric PD1-Fc-OX40L Fusion Protein, in Patients with Advanced Solid Tumors and Lymphoma." Investigational New Drugs 43, no. 2 (2025): 284. https://doi.org/10.1007/s10637-025-01518-7.

MLA (9th ed.) Citation

M, Johnson, et al. "First-in-human, Phase 1 Dose Escalation Study of SL-279252, a Hexameric PD1-Fc-OX40L Fusion Protein, in Patients with Advanced Solid Tumors and Lymphoma." Investigational New Drugs, vol. 43, no. 2, 2025, p. 284, https://doi.org/10.1007/s10637-025-01518-7.